Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
  • Published Date:
    Mar 2005
  • Source:
    Emerg Infect Dis. 11(3):411-416.
Filetype[PDF-203.46 KB]


Details:
No Related Documents.
You May Also Like:
  1. Duration of Antibody Responses after Severe Acute Respiratory Syndrome
    Personal Author:
    Wu, Li-Ping; Wang, Nai-Chang; Chang, Yi-Hua; Tian, Xiang-Yi; Na, Dan-Yu; Zhang, Li-Yuan; Zheng, Lei; Lan, Tao; Wang, Lin-Fa; Liang, Guo-Dong;
    Published Date:
    Oct 2007
    Source:
    Emerg Infect Dis. 13(10):1562-1564.
    Description:
    Among 176 patients who had had severe acute respiratory syndrome (SARS), SARS-specific antibodies were maintained for an average of 2 years, and significant reduction of immunoglobulin G-positive percentage and titers occurred in the third year. Thus...
    File Type:
    Filetype[PDF - 225.67 KB]
  2. Detection of SARS Coronavirus in Patients with Suspected SARS
    Personal Author:
    Chan, Kwok H.; Poon, Leo L.L.M.; Cheng, V.C.C.; Guan, Yi; Hung, I.F.N.; Kong, James; Yam, Loretta Y.C.; Seto, Wing H.; Yuen, Kwok Y.; Peiris, Joseph S. Malik;
    Published Date:
    Feb 2004
    Source:
    Emerg Infect Dis. 10(2):294-299.
    Description:
    Cases of severe acute respiratory syndrome (SARS) were investigated for SARS coronavirus (SARS-CoV) through RNA tests, serologic response, and viral culture. Of 537 specimens from patients in whom SARS was clinically diagnosed, 332 (60%) had SARS-CoV...
    File Type:
    Filetype[PDF - 340.32 KB]
  3. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
    Personal Author:
    Reusken, Chantal B.E.M.; Schilp, Chrispijn; Raj, V. Stalin; De Bruin, Erwin; Kohl, Robert H.G.; Farag, Elmoubasher A.B.A.; Haagmans, Bart L.; Al-Romaihi, Hamad; Le Grange, Francois; Bosch, Berend-Jan; Koopmans, Marion P.G.;
    Published Date:
    Jun 15 2016
    Source:
    Emerg Infect Dis. 22(6):1129-1131.
    File Type:
    Filetype[PDF - 359.61 KB]
  4. Neutralizing Antibody Response and SARS Severity
    Personal Author:
    Ho, Mei-Shang; Chen, Wei-Ju; Chen, Hour-Young; Lin, Szu-Fong; Wang, Min-Chin; Di, Jiali; Lu, Yen-Ta; Liu, Ching-Lung; Chang, Shan-Chwen; Chao, Chung-Liang; King, Chwan-Chuen; Chiou, Jeng-Min; Su, Ih-Jen; Yang, Jyh-Yuan;
    Published Date:
    Nov 2005
    Source:
    Emerg Infect Dis. 11(11):1730-1737.
    Description:
    Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between w...
    File Type:
    Filetype[PDF - 350.84 KB]
  5. A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease
    Personal Author:
    Selvarajah, Suganya; Sexton, Nicole R.; Kahle, Kristen M.; Fong, Rachel H.; Mattia, Kimberly-Anne; Gardner, Joy; Lu, Kai; Liss, Nathan M.; Salvador, Beatriz; Tucker, David F.; Barnes, Trevor; Mabila, Manu; Zhou, Xiangdong; Rossini, Giada; Rucker, Joseph B.; Sanders, David Avram; Suhrbier, Andreas; Sambri, Vittorio; Michault, Alain; Muench, Marcus O.; Doranz, Benjamin J.; Simmons, Graham;
    Published Date:
    Sep 12 2013
    Source:
    PLoS Negl Trop Dis. 2013; 7(9).
    Description:
    The mosquito-borne alphavirus, chikungunya virus (CHIKV), has recently reemerged, producing the largest epidemic ever recorded for this virus, with up to 6.5 million cases of acute and chronic rheumatic disease. There are currently no licensed vaccin...
    File Type:
    Filetype[PDF - 1.52 MB]